Literature DB >> 21805066

Effect of lansoprazole versus roxatidine on prevention of bleeding and promotion of ulcer healing after endoscopic submucosal dissection for superficial gastric neoplasia.

Hiroyuki Imaeda1, Naoki Hosoe, Hidekazu Suzuki, Yoshimasa Saito, Yosuke Ida, Rieko Nakamura, Yasushi Iwao, Haruhiko Ogata, Toshifumi Hibi.   

Abstract

BACKGROUND: Proton pump inhibitors have been reported to be more useful than histamine-2 receptor antagonists for the prevention of bleeding after endoscopic submucosal dissection (ESD) for superficial gastric neoplasia. The aim of this study was to assess the effects of the proton pump inhibitor lansoprazole and the histamine-2 receptor antagonist roxatidine for the prevention of bleeding and the promotion of ulcer healing after ESD and to compare the cost-effectiveness of these two drugs.
METHODS: The study subjects were 129 patients who underwent ESD for superficial gastric neoplasia. The patients were randomly assigned to the lansoprazole group (L group) or the roxatidine group (R group). Either drug was administered intravenously from the morning of the ESD day to the day after the ESD, followed by oral treatment for an additional 8 weeks. A second-look endoscopy was performed on the day after the ESD, and a repeat endoscopy was performed at 8 weeks after the ESD. The incidence of bleeding and the ulcer-healing rate at 8 weeks after the ESD were analyzed, as well as the total cost of treatment with these antisecretory agents.
RESULTS: Three patients in each group were excluded from the analysis, leaving 62 patients in L group and 61 in R group. Two of the 62 patients (3.2%) in L group and three of the 61 patients (4.9%) in R group showed bleeding after ESD ; there was no significant difference between the two groups (P = 0.68). The ulcer-healing rate was 93.5% (58/62) in L group and 93.4% (57/61) in R group (P = 1). The total cost of treatment with the antisecretory agent from the day of the ESD to day 56 after the ESD was Yen 13,212 for lansoprazole and Yen 5,841 for roxatidine.
CONCLUSIONS: Roxatidine appears to have high cost-effectiveness in the prevention of bleeding and in the promotion of ulcer healing after ESD for superficial gastric neoplasia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21805066     DOI: 10.1007/s00535-011-0447-1

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  21 in total

1.  Outcome of endoscopic mucosal resection for early gastric cancer: review of the Japanese literature.

Authors:  T Kojima; A Parra-Blanco; H Takahashi; R Fujita
Journal:  Gastrointest Endosc       Date:  1998-11       Impact factor: 9.427

2.  Cytoprotective action of roxatidine acetate HCl.

Authors:  K Shiratsuchi; H Fuse; M Hagiwara; T Mikami; K Miyasaka; H Sakuma
Journal:  Arch Int Pharmacodyn Ther       Date:  1988 Jul-Aug

3.  Endoscopic mucosal resection for treatment of early gastric cancer.

Authors:  H Ono; H Kondo; T Gotoda; K Shirao; H Yamaguchi; D Saito; K Hosokawa; T Shimoda; S Yoshida
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

4.  Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer.

Authors:  Shiro Oka; Shinji Tanaka; Iwao Kaneko; Ritsuo Mouri; Mayuko Hirata; Toru Kawamura; Masaharu Yoshihara; Kazuaki Chayama
Journal:  Gastrointest Endosc       Date:  2006-09-20       Impact factor: 9.427

5.  Endoscopic mucosal resection with a cap-fitted panendoscope for esophagus, stomach, and colon mucosal lesions.

Authors:  H Inoue; K Takeshita; H Hori; Y Muraoka; H Yoneshima; M Endo
Journal:  Gastrointest Endosc       Date:  1993 Jan-Feb       Impact factor: 9.427

Review 6.  Endoscopic resection of early gastric cancer.

Authors:  M Tada; A Murakami; M Karita; H Yanai; K Okita
Journal:  Endoscopy       Date:  1993-09       Impact factor: 10.093

7.  Effects of changing the type of H2-blocker in the treatment of H2-blocker-resistant ulcers: comparison of roxatidine acetate hydrochloride and other H2-blockers.

Authors:  K Yasutake; M Amano; Y Mizokami; S Kubota; H Fukumoto; Y Imamura; H Yokoya; K Irie
Journal:  J Int Med Res       Date:  1998 Jan-Feb       Impact factor: 1.671

8.  A prospective randomized trial of either famotidine or omeprazole for the prevention of bleeding after endoscopic mucosal resection and the healing of endoscopic mucosal resection-induced ulceration.

Authors:  Y Yamaguchi; N Katsumi; M Tauchi; M Toki; K Nakamura; K Aoki; Y Morita; M Miura; K Morozumi; H Ishida; S Takahashi
Journal:  Aliment Pharmacol Ther       Date:  2005-06       Impact factor: 8.171

Review 9.  Second-generation histamine H(2)-receptor antagonists with gastric mucosal defensive properties.

Authors:  Takafumi Ichikawa; Kyoko Hotta; Kazuhiko Ishihara
Journal:  Mini Rev Med Chem       Date:  2009-05       Impact factor: 3.862

10.  Is the Forrest classification a useful tool for planning endoscopic therapy of bleeding peptic ulcers?

Authors:  W Heldwein; J Schreiner; J Pedrazzoli; P Lehnert
Journal:  Endoscopy       Date:  1989-11       Impact factor: 10.093

View more
  14 in total

1.  Optimal duration of proton pump inhibitor for healing artificial ulcers after endoscopic submucosal dissection for early gastric cancer.

Authors:  Takuji Gotoda
Journal:  Dig Dis Sci       Date:  2011-12-25       Impact factor: 3.199

Review 2.  Proton pump inhibitors therapy vs H2 receptor antagonists therapy for upper gastrointestinal bleeding after endoscopy: A meta-analysis.

Authors:  Ying-Shi Zhang; Qing Li; Bo-Sai He; Ran Liu; Zuo-Jing Li
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 3.  Bleeding after endoscopic submucosal dissection: Risk factors and preventive methods.

Authors:  Yosuke Kataoka; Yosuke Tsuji; Yoshiki Sakaguchi; Chihiro Minatsuki; Itsuko Asada-Hirayama; Keiko Niimi; Satoshi Ono; Shinya Kodashima; Nobutake Yamamichi; Mitsuhiro Fujishiro; Kazuhiko Koike
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

Review 4.  Updated evidence on endoscopic resection of early gastric cancer from Japan.

Authors:  Mitsuhiro Fujishiro; Shuntaro Yoshida; Rie Matsuda; Akiko Narita; Hiroharu Yamashita; Yasuyuki Seto
Journal:  Gastric Cancer       Date:  2016-10-04       Impact factor: 7.370

5.  Preprocedural rabeprazole treatment before endoscopic submucosal dissection for gastric neoplasms.

Authors:  Myong Ki Baeg; Myung-Gyu Choi; Seong Jin Moon; Chul-Hyun Lim; Jin Su Kim; Yu Kyung Cho; Jae Myung Park; In Seok Lee; Sang Woo Kim; Kyu Yong Choi
Journal:  Dig Dis Sci       Date:  2014-03-27       Impact factor: 3.199

Review 6.  Second-look endoscopy and factors associated with delayed bleeding after endoscopic submucosal dissection.

Authors:  Su-Jin Kim; Cheol-Woong Choi; Dae-Hwan Kang; Hyung-Wook Kim; Su-Bum Park
Journal:  World J Gastrointest Endosc       Date:  2016-02-10

7.  Comparative efficacy of various anti-ulcer medications after gastric endoscopic submucosal dissection: a systematic review and network meta-analysis.

Authors:  Eun Hye Kim; Se Woo Park; Eunwoo Nam; Jae Gon Lee; Chan Hyuk Park
Journal:  Surg Endosc       Date:  2018-08-30       Impact factor: 4.584

8.  Proton Pump Inhibitor Therapy before and after Endoscopic Submucosal Dissection: A Review.

Authors:  Mitsushige Sugimoto; Jin Seok Jang; Yashiro Yoshizawa; Satoshi Osawa; Ken Sugimoto; Yoshihiko Sato; Takahisa Furuta
Journal:  Diagn Ther Endosc       Date:  2012-07-18

9.  A Case-Control Study of Esomeprazole Plus Rebamipide vs. Omeprazole Plus Rebamipide on Post-ESD Gastric Ulcers.

Authors:  Maki Bunno; Kyosuke Gouda; Kunihiro Yamahara; Masanori Kawaguchi
Journal:  Jpn Clin Med       Date:  2013-03-06

10.  Clinical practice guideline for endoscopic resection of early gastrointestinal cancer.

Authors:  Chan Hyuk Park; Dong-Hoon Yang; Jong Wook Kim; Jie-Hyun Kim; Ji Hyun Kim; Yang Won Min; Si Hyung Lee; Jung Ho Bae; Hyunsoo Chung; Kee Don Choi; Jun Chul Park; Hyuk Lee; Min-Seob Kwak; Bun Kim; Hyun Jung Lee; Hye Seung Lee; Miyoung Choi; Dong-Ah Park; Jong Yeul Lee; Jeong-Sik Byeon; Chan Guk Park; Joo Young Cho; Soo Teik Lee; Hoon Jai Chun
Journal:  Intest Res       Date:  2020-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.